Finorify

ZTS

Zoetis Inc.

$77.34-2.22%

Price

ZTS daily closing price
Market cap
$32.3 billion
P/E (TTM)
12.74
EV/EBITDA
6.27
52W range
$71.86 – $156.40
Div yield
1.37%
Volume
9.9M
Sector
Healthcare

Zoetis Inc. (ZTS) last closed at $77.34, on a daily price path from October 21, 2025 to October 21, 2026. Overview is that price path. Performance is the change in the close over the periods Finorify shows on the stock screen. Financials, cash flow, and margins come from reported quarters. Valuation lists the latest ratios. This snapshot is the Finorify stock screen for ZTS, covered for search and blurred for visitors.

Performance

  • 1D-0.52%
  • 5D+5.75%
  • 1M+9.28%
  • 3M+6.77%
  • 6M-32.25%
  • 1Y-45.11%
  • 5Y-59.68%

Financials

ZTS revenueQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Over the latest four reported periods ending June 30, 2026, Zoetis Inc. reported revenue of $9.52 billion.

The prior window totaled $9.38 billion, so the latest window is about the same as that stretch.

Operating cash flow in the latest window was $2.89 billion.

Free cash flow in the latest window was $2.37 billion.

These amounts are taken from Zoetis Inc.'s SEC filings and are a snapshot as of June 30, 2026. They are not a live price, and they are not a recommendation to buy or sell. Finorify uses the same filings to draw the charts inside the app.

A few ratios from those statements: Profitability: ROE 22.0% (82 of 100). Cash generation: FCF margin 24.9% (50 of 100). Net margin: 28.0% (70 of 100). Liquidity: Current 3.08× (100 of 100).

Finorify's notes from those filings, written September 21, 2026: Direct Sales and Deep Veterinarian Channel Relationships. Zoetis maintains one of the animal health industry's largest dedicated global field forces and technical support teams. Because veterinary medicines are predominantly recommended or dispensed directly by veterinarians rather than prescribed via retail pharmacies, these entrenched relationships and integrated technical support create high switching costs and an enduring commercial moat. Proprietary Innovation and Long-Lived Product Lifecycles. The company holds leading intellectual property and biologics capabilities across key therapeutic areas, such as dermatology (Apoquel, Cytopoint), pain management (Librela, Solensia), and parasiticides (Simparica Trio). Unlike human pharmaceuticals, animal health products face less abrupt 'patent cliffs' due to brand loyalty among veterinarians and lower penetration rates of generic biologics. Diversified Portfolio Across Species and Geographies. Zoetis benefits from a balanced business model split across high-margin, cash-pay companion animal treatments (driven by pet humanization) and recurring, essential livestock health products (driven by protein consumption trends). This diversification across species, product categories, and more than 100 countries insulates revenue from specific sector downturns. Emergence of Direct Therapeutics Competition. Core growth franchises in companion animal health, particularly in parasiticide combos and monoclonal antibody pain therapies, face rising competition from major animal health peers (e.g., Boehringer Ingelheim, Elanco, Merck). Competitor product launches can erode pricing power and market share. Regulatory Scrutiny and Post-Market Adverse Events. Animal pharmaceuticals and biologics are subject to rigorous oversight by agencies such as the FDA, USDA, and international equivalents. Reports of adverse side effects or negative public perception regarding novel therapeutics can lead to label changes, heightened regulatory scrutiny, litigation, or reduced veterinarian adoption. Macroeconomic Sensitivity and Agricultural Cyclicality. While veterinary care is resilient, companion animal wellness visits and premium elective treatments remain somewhat sensitive to consumer discretionary spending. Simultaneously, the livestock segment is exposed to feed costs, geopolitical trade barriers, weather extremes, and disease outbreaks among livestock populations.

Cash Flow

ZTS free cash flowQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Margins

ZTS operating margin

Valuation

P/E (TTM)
12.74
P/S (TTM)
3.39
EV/EBITDA
6.27

Insights

Advantage

Direct Sales and Deep Veterinarian Channel Relationships

Zoetis maintains one of the animal health industry's largest dedicated global field forces and technical support teams. Because veterinary medicines are predominantly recommended or dispensed directly by veterinarians rather than prescribed via retail pharmacies, these entrenched relationships and integrated technical support create high switching costs and an enduring commercial moat.

Advantage

Proprietary Innovation and Long-Lived Product Lifecycles

The company holds leading intellectual property and biologics capabilities across key therapeutic areas, such as dermatology (Apoquel, Cytopoint), pain management (Librela, Solensia), and parasiticides (Simparica Trio). Unlike human pharmaceuticals, animal health products face less abrupt 'patent cliffs' due to brand loyalty among veterinarians and lower penetration rates of generic biologics.

Advantage

Diversified Portfolio Across Species and Geographies

Zoetis benefits from a balanced business model split across high-margin, cash-pay companion animal treatments (driven by pet humanization) and recurring, essential livestock health products (driven by protein consumption trends). This diversification across species, product categories, and more than 100 countries insulates revenue from specific sector downturns.

Risk

Emergence of Direct Therapeutics Competition

Core growth franchises in companion animal health, particularly in parasiticide combos and monoclonal antibody pain therapies, face rising competition from major animal health peers (e.g., Boehringer Ingelheim, Elanco, Merck). Competitor product launches can erode pricing power and market share.

Risk

Regulatory Scrutiny and Post-Market Adverse Events

Animal pharmaceuticals and biologics are subject to rigorous oversight by agencies such as the FDA, USDA, and international equivalents. Reports of adverse side effects or negative public perception regarding novel therapeutics can lead to label changes, heightened regulatory scrutiny, litigation, or reduced veterinarian adoption.

Risk

Macroeconomic Sensitivity and Agricultural Cyclicality

While veterinary care is resilient, companion animal wellness visits and premium elective treatments remain somewhat sensitive to consumer discretionary spending. Simultaneously, the livestock segment is exposed to feed costs, geopolitical trade barriers, weather extremes, and disease outbreaks among livestock populations.

Read the live analysis in Finorify

Charts, news, and the written notes are in the app. You can open five distinct stocks free. After that, the stock screen is a Finorify Pro feature.

Open ZTS in Finorify